BTIG Research Increases LifeStance Health Group (NASDAQ:LFST) Price Target to $16.00

LifeStance Health Group (NASDAQ:LFST) had its target price upped by research analysts at BTIG Research from $15.00 to $16.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. BTIG Research’s price objective points to a potential upside of 50.09% from the stock’s previous close.

A number of other analysts have also weighed in on LFST. Canaccord Genuity Group upped their target price on shares of LifeStance Health Group from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. KeyCorp raised their price objective on LifeStance Health Group from $11.00 to $13.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. JPMorgan Chase & Co. lifted their target price on shares of LifeStance Health Group from $8.00 to $9.00 and gave the company a “neutral” rating in a report on Thursday, May 14th. Zacks Research cut LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Finally, The Goldman Sachs Group initiated coverage on shares of LifeStance Health Group in a research report on Friday, June 5th. They set a “neutral” rating and a $9.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $11.62.

LifeStance Health Group Trading Up 2.8%

Shares of NASDAQ LFST opened at $10.66 on Friday. The stock has a market capitalization of $4.13 billion, a PE ratio of 177.67 and a beta of 1.14. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.18. The stock has a fifty day simple moving average of $9.88 and a 200-day simple moving average of $8.03. LifeStance Health Group has a twelve month low of $3.81 and a twelve month high of $11.76.

LifeStance Health Group (NASDAQ:LFST) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.03. LifeStance Health Group had a net margin of 1.55% and a return on equity of 1.56%. The business had revenue of $435.35 million for the quarter, compared to analysts’ expectations of $414.58 million. During the same quarter in the prior year, the company earned ($0.01) earnings per share. The business’s quarterly revenue was up 26.1% on a year-over-year basis. On average, equities analysts forecast that LifeStance Health Group will post 0.12 earnings per share for the current year.

Insider Activity at LifeStance Health Group

In other LifeStance Health Group news, Director Darren M. Black sold 5,899,661 shares of the company’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $8.02, for a total value of $47,315,281.22. Following the transaction, the director directly owned 23,310,115 shares in the company, valued at approximately $186,947,122.30. This represents a 20.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Robert Bessler sold 894,337 shares of the business’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $10.13, for a total value of $9,059,633.81. Following the completion of the transaction, the director owned 539,763 shares of the company’s stock, valued at $5,467,799.19. This trade represents a 62.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 7,612,394 shares of company stock valued at $62,938,451 over the last quarter. Insiders own 3.50% of the company’s stock.

Institutional Investors Weigh In On LifeStance Health Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in LFST. Royal Bank of Canada raised its position in LifeStance Health Group by 63.4% in the first quarter. Royal Bank of Canada now owns 70,248 shares of the company’s stock valued at $468,000 after purchasing an additional 27,244 shares during the period. AQR Capital Management LLC raised its stake in LifeStance Health Group by 223.0% during the first quarter. AQR Capital Management LLC now owns 51,500 shares of the company’s stock valued at $343,000 after buying an additional 35,554 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in LifeStance Health Group by 3.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 142,950 shares of the company’s stock worth $952,000 after purchasing an additional 4,169 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of LifeStance Health Group by 1.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 615,652 shares of the company’s stock worth $4,100,000 after purchasing an additional 11,331 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in LifeStance Health Group by 10.2% in the second quarter. JPMorgan Chase & Co. now owns 550,657 shares of the company’s stock worth $2,847,000 after acquiring an additional 51,154 shares during the last quarter. 85.50% of the stock is currently owned by institutional investors and hedge funds.

LifeStance Health Group News Summary

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: LifeStance reported second-quarter revenue of $435.4 million, up 26% year over year and above analysts’ $414.6 million estimate. Earnings were $0.06 per share versus the $0.03 consensus and a $0.01 loss in the prior-year quarter. LifeStance Health Group Tops Q2 Earnings and Revenue Estimates
• Positive Sentiment: Profitability improved sharply: net income reached $23.6 million versus a $3.8 million loss a year ago, while adjusted EBITDA nearly doubled to $66.0 million. Visit volumes rose 19% to 2.6 million, supported by an 11% increase in the clinician base to 8,542. LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook
• Positive Sentiment: Management raised 2026 revenue guidance to $1.685 billion-$1.725 billion, along with adjusted EBITDA guidance of $215 million-$235 million. Third-quarter revenue guidance of $420 million-$440 million also exceeds the roughly $417.7 million analyst consensus. LifeStance Swings to Q2 Profit and Raises 2026 Revenue Guidance
• Positive Sentiment: The board authorized up to $100 million in additional common-stock repurchases under a replacement program, while quarterly operating cash flow reached $99.9 million. LifeStance Reports 26% Q2 Revenue Growth and Raises Outlook
• Neutral Sentiment: The earnings call emphasized expansion into new geographies, broader clinical specialties, clinician growth, and measurable patient outcomes as longer-term growth drivers. LifeStance Q2 2026 Earnings Call Transcript
• Negative Sentiment: Despite the strong results, LFST trades at a high earnings multiple, cash of $225.9 million remains below net long-term debt of $259.0 million, and reported insider transactions have been dominated by selling. These factors could limit further upside if growth or profitability slows.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.